Paul Vana, MD
Family Medicine · Omaha, NENPI 1770685075
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Intuitive Surgical at 56.5% of the total. 2025 is the largest year on record at $6,551, 5.8 times the $1,127 reported in 2019. Among family medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AbbVie$718
- Novo Nordisk$679
- Pfizer$542
- Amgen$391
- AstraZeneca$371
- plus $2K from 43 others
What the payments were for
- Travel & lodging$6,54556%
- Food & beverage$4,99543%
- Education$781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,137
- SYMBICORT$214
- FARXIGA$214
How this compares
$11,617 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $67,556 |
| JardianceEmpagliflozin | 48 | $41,360 |
| TrulicityDulaglutide | 43 | $41,059 |
| JanuviaSitagliptin Phosphate | 38 | $38,025 |
| OzempicSemaglutide | 37 | $34,208 |
| FarxigaDapagliflozin Propanediol | 32 | $27,120 |
| MounjaroTirzepatide | 23 | $26,275 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $21,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $17,395 |
| XareltoRivaroxaban | 21 | $17,304 |
| Spiriva HandihalerTiotropium Bromide | 17 | $12,500 |
| MyrbetriqMirabegron | 16 | $11,645 |
| Bydureon BciseExenatide Microspheres | 16 | $11,501 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $9,427 |
| TrintellixVortioxetine Hydrobromide | 11 | $9,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $542 | $67,55676 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $345 | $67,33366 claims |
| MerckJanuvia, Janumet | $17 | $59,07855 claims |
| Boehringer IngelheimJardiance | $152 | $41,36048 claims |
| Novo NordiskOzempic | $679 | $34,20837 claims |
| AstraZenecaFarxiga | $371 | $27,12032 claims |
| GSKTrelegy Ellipta | $23 | $17,39516 claims |
| Johnson & JohnsonXarelto | $114 | $17,30421 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $11,64516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $152 | $9,11311 claims |
| AbbVieCombigan, Synthroid | $718 | $4,92245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Gerard StanleyOmaha$50K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
- Christopher ConnollyOmaha$12K
- Stephen TetraultOmaha$11K
- James RamigOmaha$11K
- Jeffrey RappOmaha$10K
- Christine Carlson RahnOmaha$10K
- Joseph DumbaOmaha$10K
- Charles RogersOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.